UniQure's gene therapy continues to slow Huntington's progression after four years

UniQure reported that its gene therapy for Huntington’s disease continues to slow the illness’s progression after four years of follow-up, according to STAT News. The new analysis extends data the company previously disclosed roughly a year earlier, which had shown a similar slowing effect on disease course in treated patients.

STAT News reported that the magnitude of the benefit has waned somewhat compared to that earlier analysis. The report did not specify the exact figures behind either measurement in the material available, only that the newer four-year data showed a smaller effect size than the prior readout.

Huntington’s disease is a fatal, inherited neurodegenerative condition with no approved treatment that alters its underlying course. Gene therapies aimed at slowing or halting progression have been in development for years across the field, with long-term durability remaining one of the central open questions for any such approach.

STAT News framed the persistence of a treatment effect at the four-year mark as notable given how few interventions for the disease have produced any durable signal at all. The outlet’s account did not include projections for how the therapy might perform beyond this follow-up period, nor did it detail regulatory next steps for the program based on the data described.